Cancer statistics, CA Cancer J. Clin, vol.69, pp.7-34, 2019. ,
The epidemiology of renal cell carcinoma, Eur. Urol, vol.60, pp.615-621, 2011. ,
Vhl, the story of a tumour suppressor gene, Nat. Rev. Cancer, vol.15, pp.55-64, 2015. ,
Axitinib for the treatment of advanced renal cell carcinoma, Expert Opin. Pharmacother, vol.15, pp.283-297, 2014. ,
Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med, vol.369, pp.722-731, 2013. ,
Cabozantinib versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med, vol.373, pp.1814-1823, 2015. ,
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (tivo-3): A phase 3, multicentre, randomised, controlled, open-label study, Lancet Oncol, vol.21, pp.95-104, 2020. ,
The 2016 who classification of tumours of the urinary system and male genital organs-part a: Renal, penile, and testicular tumours, Eur. Urol, vol.70, pp.93-105, 2016. ,
Comprehensive molecular characterization of papillary renal-cell carcinoma, N. Engl. J. Med, vol.374, pp.135-145, 2016. ,
Mit family translocation renal cell carcinoma, Semin. Diagn. Pathol, vol.32, pp.103-113, 2015. ,
Genomic heterogeneity of translocation renal cell carcinoma, Clin. Cancer Res, vol.19, pp.4673-4684, 2013. ,
Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas, Sci. Rep, vol.6, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01357776
Genomic characterization of renal medullary carcinoma and treatment outcomes, Clin. Genitourin. Cancer, vol.15, pp.987-994, 2017. ,
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: Recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry, Am. J. Surg. Pathol, vol.38, pp.627-637, 2014. ,
Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations, Eur. Urol, vol.70, pp.348-357, 2016. ,
Updated european association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma, Eur. Urol, vol.76, pp.151-156, 2019. ,
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J. Clin. Oncol, vol.20, pp.289-296, 2002. ,
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol, vol.13, pp.688-696, 1995. ,
, Int. J. Mol. Sci, 2020.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med, vol.356, pp.115-124, 2007. ,
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N. Engl. J. Med, vol.378, pp.1277-1290, 2018. ,
Nivolumab versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015. ,
Pd-l1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis, Diagn. Pathol, vol.10, 2015. ,
Implications of b7-h1 expression in clear cell carcinoma of the kidney for prognostication and therapy, Clin. Cancer Res, vol.13, pp.709-715, 2007. ,
Pd-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma, Clin. Cancer Res, vol.13, pp.1757-1761, 2007. ,
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med, vol.380, pp.1103-1115, 2019. ,
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med, vol.380, pp.1116-1127, 2019. ,
Primary, adaptive, and acquired resistance to cancer immunotherapy, vol.168, pp.707-723, 2017. ,
Cancer immunoediting: From immunosurveillance to tumor escape, Nat. Immunol, vol.3, pp.991-998, 2002. ,
Lag-3, tim-3, and tigit: Co-inhibitory receptors with specialized functions in immune regulation, Immunity, vol.44, pp.989-1004, 2016. ,
Phenotype molding of stromal cells in the lung tumor microenvironment, Nat. Med, vol.24, pp.1277-1289, 2018. ,
Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors, Am. J. Pathol, vol.175, pp.2657-2667, 2009. ,
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma, Hum. Pathol, vol.43, 1982. ,
URL : https://hal.archives-ouvertes.fr/inserm-00702346
Sunitinib stimulates expression of vegfc by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas, Cancer Res, vol.77, pp.1212-1226, 2017. ,
Tumor b7-h1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res, vol.66, pp.3381-3385, 2006. ,
Pd-l1 expression in nonclear-cell renal cell carcinoma, Ann. Oncol, vol.25, pp.2178-2184, 2014. ,
1) amplifications in renal cell carcinomas with sarcomatoid transformation: Implications for clinical management, Mod. Pathol, vol.32, pp.1344-1358, 2019. ,
An immune atlas of clear cell renal cell carcinoma, vol.169, pp.736-749, 2017. ,
Tumor-infiltrating and peripheral blood t-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma, Clin. Cancer Res, vol.23, pp.4416-4428, 2017. ,
A minority-group of renal cell cancer patients with high infiltration of cd20 + b-cells is associated with poor prognosis, Br. J. Cancer, vol.119, pp.840-846, 2018. ,
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma, Clin. Cancer Res, vol.22, pp.5461-5471, 2016. ,
Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report, Mol. Clin. Oncol, vol.10, pp.244-248, 2019. ,
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (immotion151): A multicentre, open-label, phase 3, randomised controlled trial, Lancet, vol.393, pp.2404-2415, 2019. ,
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, Lancet Oncol, vol.20, pp.1370-1385, 2019. ,
Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions, Eur. Urol, vol.75, pp.100-110, 2019. ,
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the checkmate 025 study, Jpn. J. Clin. Oncol, vol.47, pp.639-646, 2017. ,
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy, N. Engl. J. Med, vol.375, pp.2246-2254, 2016. ,
Nccn guidelines insights: Kidney cancer, version 2.2020, J. Natl. Compr. Cancer Netw, vol.17, pp.1278-1285, 2019. ,
Systemic therapy for non-clear cell renal cell carcinomas: A systematic review and meta-analysis, Eur. Urol, vol.67, pp.740-749, 2015. ,
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma, J. Immunother. Cancer, vol.6, issue.9, 2018. ,
Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade, Cell, vol.167, pp.1540-1554, 2016. ,
Tim-3 expression characterizes regulatory t cells in tumor tissues and is associated with lung cancer progression, PLoS ONE, vol.7, 2012. ,
Targeting tim-3 and pd-1 pathways to reverse t cell exhaustion and restore anti-tumor immunity, J. Exp. Med, vol.207, pp.2187-2194, 2010. ,
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines, Cancer Immunol. Immunother, vol.58, pp.1517-1526, 2009. ,
, Int. J. Mol. Sci, 2020.
Relationship of b7-h3 expression in tumor cells and tumor vasculature with foxp3+ regulatory t cells in renal cell carcinoma, Cancer Manag. Res, vol.11, pp.7021-7030, 2019. ,
Vista, a novel mouse ig superfamily ligand that negatively regulates t cell responses, J. Exp. Med, vol.208, pp.577-592, 2011. ,
Vista regulates the development of protective antitumor immunity, Cancer Res, vol.74, pp.1933-1944, 2014. ,
Icos ligation recruits the p50alpha pi3k regulatory subunit to the immunological synapse, J. Immunol, vol.181, pp.1969-1977, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00282605
Rationale for anti-ox40 cancer immunotherapy, Eur. J. Cancer, vol.52, pp.50-66, 2016. ,
The gitr-gitrl interaction: Co-stimulation or contrasuppression of regulatory activity?, Nat. Rev. Immunol, vol.6, pp.613-618, 2006. ,
Altered cancer metabolism in mechanisms of immunotherapy resistance, Pharmacol. Ther, vol.195, pp.162-171, 2019. ,
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression, Breast Cancer Res, vol.16, p.410, 2014. ,
Targeting the ido1/tdo2-kyn-ahr pathway for cancer immunotherapy-challenges and opportunities, Trends Pharmacol. Sci, vol.39, pp.307-325, 2018. ,
Targeting adenosine for cancer immunotherapy, J. Immunother. Cancer, vol.6, 2018. ,
Adenosine regulates cd8 t-cell priming by inhibition of membrane-proximal t-cell receptor signalling, Immunology, vol.128, pp.728-737, 2009. ,
Targeting amino acid metabolism in cancer growth and anti-tumor immune response, World J. Biol. Chem, vol.6, pp.281-289, 2015. ,
Cancer epigenetics: From mechanism to therapy, Cell, vol.150, pp.12-27, 2012. ,
Histone deacetylase inhibitors as anticancer drugs, Int. J. Mol. Sci, vol.18, 2017. ,
Recent development and clinical application of cancer vaccine: Targeting neoantigens, J. Immunol. Res, 2018. ,
Caix-specific car-t cells and sunitinib show synergistic effects against metastatic renal cancer models, J. Immunother, vol.43, pp.16-28, 2020. ,
External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: A population-based study, Lancet Oncol, vol.14, pp.141-148, 2013. ,
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma, Cancer, vol.119, pp.1547-1554, 2013. ,
Targeting the pd-1/pd-l1 pathway in renal cell carcinoma, Int. J. Mol. Sci, 1692. ,
URL : https://hal.archives-ouvertes.fr/hal-02119178
High ido-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma, Cancer Sci, vol.109, pp.1583-1591, 2018. ,
, Int. J. Mol. Sci, 2020.
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting, Clin. Cancer Res, vol.21, pp.1329-1339, 2015. ,
Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer-data from a randomized phase iii trial, Cancer Discov, vol.9, pp.510-525, 2019. ,
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat. Med, vol.24, pp.749-757, 2018. ,
Pd-1 and pd-l1 expression in renal cell carcinoma with sarcomatoid differentiation, Cancer Immunol. Res, vol.3, pp.1303-1307, 2015. ,
A consensus molecular classification of muscle-invasive bladder cancer, Eur. Urol, vol.77, pp.420-433, 2019. ,
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.9, 2017. ,
Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups, Cancer Immunol. Res, vol.4, pp.820-822, 2016. ,
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, vol.359, pp.801-806, 2018. ,
Microsatellite instability as a biomarker for pd-1 blockade, Clin. Cancer Res, vol.22, pp.813-820, 2016. ,
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer, Ann. Oncol, vol.29, pp.1437-1444, 2018. ,
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression, Genome Biol, vol.17, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01398093
Intratumour heterogeneity in urologic cancers: From molecular evidence to clinical implications, Eur. Urol, vol.67, pp.729-737, 2015. ,
Single-cell rna sequencing in cancer: Lessons learned and emerging challenges, Mol. Cell, vol.75, pp.7-12, 2019. ,
Application of single-cell rna sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma, Genome Biol, vol.17, 2016. ,
Ex-vivo treatment of tumor tissue slices as a predictive preclinical method to evaluate targeted therapies for patients with renal carcinoma, Cancers ,
URL : https://hal.archives-ouvertes.fr/inserm-02465631
Ex vivo tumor culture systems for functional drug testing and therapy response prediction, Future Sci ,
Mobilization of cd8( + ) t cells via cxcr4 blockade facilitates pd-1 checkpoint therapy in human pancreatic cancer, Clin. Cancer Res, vol.25, pp.3934-3945, 2019. ,
Generation of tumor-reactive t cells by co-culture of peripheral blood lymphocytes and tumor organoids, Cell, vol.174, pp.1586-1598, 2018. ,
, Int. J. Mol. Sci, 2020.
)zr-atezolizumab imaging as a non-invasive approach to assess clinical response to pd-l1 blockade in cancer, Nat. Med, vol.24, issue.89, pp.1852-1858, 2018. ,
A radiomics approach to assess tumour-infiltrating cd8 cells and response to anti-pd-1 or anti-pd-l1 immunotherapy: An imaging biomarker, retrospective multicohort study, Lancet Oncol, vol.19, pp.1180-1191, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01958243
Circulating tumor cells and "suspicious objects" evaluated through cellsearch(r) in metastatic renal cell carcinoma, Anticancer. Res, vol.31, pp.4219-4221, 2011. ,
Epithelial-to-mesenchymal transition in renal neoplasms, Adv. Anat. Pathol, vol.21, pp.174-180, 2014. ,
Combined cell surface carbonic anhydrase 9 and cd147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients, Oncotarget, vol.7, pp.59877-59891, 2016. ,
Circulating tumor cells in renal cell carcinoma: Recent findings and future challenges, Front. Oncol, vol.9, p.228, 2019. ,
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI